Halobetasol Propionate + Tazarotene interactions

Checked as Ulobetasol (topical) + Tazarotene in this data source.

Full monograph for Halobetasol Propionate + Tazarotene Check it against another medicine

Medicines

84 documented

Severity

Medicines documented to interact with Halobetasol Propionate + Tazarotene, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Acarbosevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Alogliptin Benzoatevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Biphasic Insulin Aspartvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Canagliflozin Hemihydratevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Dapagliflozin Propanediolvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Dulaglutidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Empagliflozinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Empagliflozin + Linagliptinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Empagliflozin + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Ertugliflozinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Glibenclamidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Glimepiridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Glimepiride + Metforminvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Glipizidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Glipizide + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Insulin Aspartvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Aspart + Insulin Aspart Protaminevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Insulin Aspart [Protamine Crystallised]via Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Degludecvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Degludec + Insulin Aspart Premixedvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Insulin Detemirvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Glarginevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Glulisinevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Human [rDNA]via Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Lisprovia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Insulin Lispro Protamine + Insulin Lisprovia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Linagliptinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Linagliptin + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Liraglutidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Miglitolvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Pioglitazonevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Pioglitazone + Glimepiridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Pioglitazone + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Regular Insulin Human + Isophane Insulin Humanvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Repaglinidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Saxagliptinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Semaglutidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Sitagliptinvia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry
Sitagliptin + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…2 documented mechanisms	18 sources — open the full entry
Tirzepatidevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	8 sources — open the full entry
Vildagliptin + Metformin Hydrochloridevia Ulobetasol (topical)	Minor	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use…	18 sources — open the full entry

Conditions

Conditions in which Halobetasol Propionate + Tazarotene needs care, as documented in this source.

Adrenocortical Hyperfunction
Moderate
The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism. Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression. Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Patients with an altered skin barrier or liver failure are also at increased risk. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.
32 sources
1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
2. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
3. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
4. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
5. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
6. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
7. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
8. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
Show all 32 sourcesShow fewer sources
1. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
2. Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990): 107-11
3. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
4. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
5. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
6. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
7. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
8. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
9. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
10. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
11. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
12. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
13. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
14. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
15. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
16. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
17. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
18. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
19. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
20. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
21. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
22. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
23. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
24. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Adrenocortical Hyperfunction
Moderate
The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism. Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression. Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Patients with an altered skin barrier or liver failure are also at increased risk. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.
32 sources
1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
2. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
3. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
4. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
5. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
6. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
7. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
8. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
Show all 32 sourcesShow fewer sources
1. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
2. Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990): 107-11
3. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
4. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
5. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
6. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
7. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
8. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
9. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
10. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
11. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
12. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
13. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
14. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
15. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
16. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
17. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
18. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
19. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
20. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
21. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
22. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
23. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
24. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Diabetes Mellitus
Moderate
Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.
23 sources
1. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
2. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
3. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
4. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
5. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
6. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
7. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
8. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
Show all 23 sourcesShow fewer sources
1. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
2. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
3. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
4. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
5. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
6. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
7. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
8. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
9. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
10. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
11. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
12. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
13. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
14. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
15. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Diabetes Mellitus
Moderate
Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.
23 sources
1. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
2. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
3. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
4. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
5. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
6. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
7. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
8. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
Show all 23 sourcesShow fewer sources
1. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
2. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
3. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
4. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
5. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
6. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
7. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
8. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
9. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
10. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
11. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
12. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
13. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
14. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
15. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Diaper Rash
Moderate
Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing's syndrome and intracranial hypertension because of their larger skin surface to body mass ratios. If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.
37 sources
1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
2. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
3. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
4. Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979): 362-3
5. Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993): 501-3
6. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
7. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
8. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
Show all 37 sourcesShow fewer sources
1. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
2. Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987): 422-4
3. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
4. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
5. Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983): 59-71
6. Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977): 1196-202
7. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
8. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
9. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
10. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
11. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
12. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
13. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
14. Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995): 950-5
15. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
16. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
17. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
18. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
19. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
20. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
21. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
22. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
23. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
24. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
25. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
26. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
27. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
28. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
29. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Diaper Rash
Moderate
Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing's syndrome and intracranial hypertension because of their larger skin surface to body mass ratios. If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.
37 sources
1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
2. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
3. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
4. Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979): 362-3
5. Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993): 501-3
6. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
7. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
8. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
Show all 37 sourcesShow fewer sources
1. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
2. Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987): 422-4
3. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
4. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
5. Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983): 59-71
6. Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977): 1196-202
7. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
8. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
9. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
10. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
11. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
12. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
13. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
14. Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995): 950-5
15. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
16. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
17. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
18. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
19. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
20. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
21. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
22. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
23. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
24. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
25. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
26. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
27. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
28. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
29. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Infections
Moderate
Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used. Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Occlusive dressings should not be used in patients with skin infection.
24 sources
1. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
2. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
3. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
4. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
5. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
6. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
7. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
8. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
Show all 24 sourcesShow fewer sources
1. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
2. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
3. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
4. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
5. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
6. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
7. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
8. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
9. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
10. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
11. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
12. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
13. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
14. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
15. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
16. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Infections
Moderate
Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used. Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Occlusive dressings should not be used in patients with skin infection.
24 sources
1. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
2. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
3. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
4. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
5. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
6. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
7. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
8. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
Show all 24 sourcesShow fewer sources
1. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
2. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
3. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
4. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
5. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
6. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
7. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
8. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
9. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
10. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
11. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
12. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
13. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
14. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
15. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
16. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Toxic Optic Neuropathy
Moderate
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.
27 sources
1. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
2. Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983): 878-81
3. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
4. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993): 664-6
5. Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976): 207-8
6. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
7. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
8. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
Show all 27 sourcesShow fewer sources
1. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
2. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
3. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
4. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
5. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
6. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
7. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
8. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
9. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
10. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
11. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
12. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
13. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
14. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
15. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
16. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
17. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
18. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
19. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):
Toxic Optic Neuropathy
Moderate
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.
27 sources
1. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
2. Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983): 878-81
3. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
4. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993): 664-6
5. Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976): 207-8
6. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
7. "Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc (2022):
8. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc (2001):
Show all 27 sourcesShow fewer sources
1. "Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb
2. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):
3. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome (2001):
4. "Product Information. Diprolene (betamethasone topical)." Schering Corporation (2001):
5. "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome
6. "Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc (2001):
7. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome (2001):
8. "Product Information. Cyclocort (amcinonide topical)." Fujisawa (2001):
9. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc (2001):
10. "Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel
11. "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer (2001):
12. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc (2001):
13. "Product Information. Elocon (mometasone topical)." Schering Corporation (2001):
14. "Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma (2022):
15. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa (2001):
16. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation (2001):
17. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals (2001):
18. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories (2001):
19. "Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc (2001):

Medicines

Conditions

Adrenocortical Hyperfunction

Adrenocortical Hyperfunction

Diabetes Mellitus

Diabetes Mellitus

Diaper Rash

Diaper Rash

Infections

Infections

Toxic Optic Neuropathy

Toxic Optic Neuropathy